Tazarotene 0.1% Topical

Indications

Tazarotene 0.1% Topical is used for: Acne, Stable plaque psoriasis, Photo aging

Adult Dose

Topical/Cutaneous Acne, Stable plaque psoriasis Apply a thin layer to cleansed dry affected area, once daily in the evening. Photoaging Adult: Apply a thin layer to cover entire face (including eyelids) once daily before going to bed.

Child Dose

<12 years: Safety and efficacy not established >12 years: Apply to affected area once daily in the evening.

Renal Dose

Administration

Contra Indications

Pregnancy, lactation. Eczema. Sunburnt conditions. Hypersensitivity.

Precautions

Avoid contact with eyes, mouth, mucous membranes. Abraded skin. Avoid exposure to sun or UV light. Do not use >10% of BSA. Do not use cream with occlusive dressing. Wash hands after application. Do not use cream/gel in amounts more than instructed. Women of child bearing potential should take birth control measures. Negative pregnancy test to be obtained within 2 wk prior to initiation and start therapy during normal menstrual period. Retinoid should not be used on eczematous skin, as they may cause severe irritation. Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary and in such cases, exposure should be minimized during the use of Tazarotene cream. Tazarotene cream should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.

Pregnancy-Lactation

Pregnancy There are no adequate and well-controlled studies with use in pregnant women Contraindicated in females who are or may become pregnant Based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy; safety in pregnant females has not been established; the potential risk to the fetus outweighs the potential benefit to the mother during pregnancy; therefore, discontinue as soon as pregnancy is recognized Females of childbearing potential Pregnancy testing Pregnancy testing is recommended within 2 weeks before initiating therapy, which should begin during a menstrual period Contraception Based on animal studies, fetal harm may occur when administered to a pregnant woman Advise to use effective contraception during treatment Lactation Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from the underlying maternal condition Clinical considerations To minimize potential exposure to the breastfed infant via breast milk, use for the shortest duration possible while breastfeeding Advise breastfeeding patients not to apply directly to the nipple and areola to prevent direct infant exposure

Interactions

Increased drying effect effect with concomitant use of dermatologic medications and cosmetics that have irritant or strong drying effect. Increased risk of photosensitivity with drugs known to be photosensitisers.

Adverse Effects

Side effects of Tazarotene 0.1% Topical : >10% Desquamation, Erythema, Burning/stinging, Dry skin 1-10% Skin irritation (1% -22%), Skin pain, Pruritis, Irritant or contact dermatitis, Stinging, Acne, Photosensitivity, Rash, Cheilitis Frequency Not Defined Worsening of psoriasis, Eczema, Rash, Dry skin, Skin inflammation, Fissuring, Bleeding, Peripheral edema, Hypertriglyceridemia

Mechanism of Action

Tazarotene is a synthetic acetylenic retinoid, that is applied topically. It is de-esterified in the skin to its active form, tazarotenic acid, which affects cell proliferation and differentiation by modulating gene expression in acne and psoriasis.